Combining Hypothermia and Oleuropein Subacutely Protects Subcortical White Matter in a Swine Model of Neonatal Hypoxic-Ischemic Encephalopathy

J Neuropathol Exp Neurol. 2021 Jan 20;80(2):182-198. doi: 10.1093/jnen/nlaa132.

Abstract

Neonatal hypoxia-ischemia (HI) causes white matter injury that is not fully prevented by therapeutic hypothermia. Adjuvant treatments are needed. We compared myelination in different piglet white matter regions. We then tested whether oleuropein (OLE) improves neuroprotection in 2- to 4-day-old piglets randomized to undergo HI or sham procedure and OLE or vehicle administration beginning at 15 minutes. All groups received overnight hypothermia and rewarming. Injury in the subcortical white matter, corpus callosum, internal capsule, putamen, and motor cortex gray matter was assessed 1 day later. At baseline, piglets had greater subcortical myelination than in corpus callosum. Hypothermic HI piglets had scant injury in putamen and cerebral cortex. However, hypothermia alone did not prevent the loss of subcortical myelinating oligodendrocytes or the reduction in subcortical myelin density after HI. Combining OLE with hypothermia improved post-HI subcortical white matter protection by preserving myelinating oligodendrocytes, myelin density, and oligodendrocyte markers. Corpus callosum and internal capsule showed little HI injury after hypothermia, and OLE accordingly had minimal effect. OLE did not affect putamen or motor cortex neuron counts. Thus, OLE combined with hypothermia protected subcortical white matter after HI. As an adjuvant to hypothermia, OLE may subacutely improve regional white matter protection after HI.

Keywords: BIN1; Cardiac arrest; Hypothermia; Hypoxia; Myelin basic protein; Neonate; White matter.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Brain / drug effects*
  • Brain / pathology
  • Combined Modality Therapy
  • Disease Models, Animal
  • Hypothermia, Induced*
  • Hypoxia-Ischemia, Brain / pathology
  • Hypoxia-Ischemia, Brain / therapy*
  • Iridoid Glucosides / pharmacology*
  • Iridoid Glucosides / therapeutic use
  • Myelin Sheath / drug effects
  • Myelin Sheath / pathology
  • Neuroprotection / physiology*
  • Neuroprotective Agents / therapeutic use*
  • Swine
  • White Matter / drug effects*
  • White Matter / pathology

Substances

  • Iridoid Glucosides
  • Neuroprotective Agents
  • oleuropein